title: Anti-IL-23p19 therapy inhibits the adoptive transfer of syngeneic graft-versus-host disease.
abstract: Syngeneic graft-versus-host disease (SGVHD), a chronic inflammatory disease, develops following irradiation, syngeneic bone marrow transplantation (BMT) and treatment with the immunosuppressive agent cyclosporine A (CsA). We have shown that TH1 and TH17 cytokine responses are increased during the development of SGVHD. The current study was designed to further investigate the involvement of TH17 immunity in SGVHD-associated colitis. IL-23 is a TH17 cytokine responsible for maintaining the effector functions of TH17 cells. The administration of anti-mouse IL-23p19 was shown to significantly reduce the clinical symptoms of primary and secondary SGVHD-associated colitis resulting in a significant reduction in both TH1 and TH17 associated cytokine expression. These results demonstrate that the TH17-associated cytokine, IL-23, may prove to be a beneficial therapeutic target in the treatment of chronic colon inflammation.
authors: Departments of Microbiology, Immunology and Molecular Genetics, University of Kentucky Medical Center, Lexington, KY 40536, USA.
authors: J Anthony
authors: JA
authors: Brandon
authors: C Darrell
authors: CD
authors: Jennings
authors: Alan M
authors: AM
authors: Kaplan
authors: J Scott
authors: JS
authors: Bryson
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology* / Q000628:therapy*; D018836:Inflammation Mediators / Q000378:metabolism; D053760:Interleukin-23 Subunit p19 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051379:Mice; D014185:Transplantation, Isogeneic
chemical_list: D016207:Cytokines; D018836:Inflammation Mediators; D053760:Interleukin-23 Subunit p19